June 15, 2005 08:31 ET

DNAPrint Selects Proteos to Manufacture Therapeutic Product for Preclinical Evaluation, Announces The OTC Report

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The OTC Report.

LAKE HARMONY, PA -- (MARKET WIRE) -- June 15, 2005 -- The OTC Report recommends DNAPrint Genomics, Inc. (OTC BB: DNAP), which announced that it has selected Proteos, Inc. to manufacture the first batch of its new therapeutic candidate PT-401 (Super EPO dimer) for pre-clinical testing.

"Proteos has 20 years of experience in protein and peptide chemistry and has proven its ability as a Contract Research Organization (CRO) dealing with biologically complex therapeutics," stated DNAPrint Chief Medical Officer Hector Gomez, M.D., Ph. D. "The selection of Proteos is the culmination of a competitive bidding process solicited by DNAPrint management. In addition, Proteos' staff has previously worked with erythropoietin (EPO), the simpler, monomer form of the drug that major pharmaceutical companies currently have on the market."

For more information visit

Other active stocks are Manugistics Group Inc (NASDAQ: MANU), Isonics Corp (NASDAQ: ISON) and Vasco Data Security International (NASDAQ: VDSI).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. The company has hired and paid $595.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact Information